We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+11.22%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$10.3B
AUM Growth
+$1.27B
Cap. Flow
+$755M
Cap. Flow %
7.32%
Top 10 Hldgs %
81.62%
Holding
100
New
12
Increased
23
Reduced
8
Closed
11

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$212M
2
INSM icon
Insmed
INSM
+$178M
3
ALKS icon
Alkermes
ALKS
+$57.4M
4
RVMD icon
Revolution Medicines
RVMD
+$54.9M
5
GPCR icon
Structure Therapeutics
GPCR
+$47.2M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$23.2M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$22.3M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$17.6M
4
TSVT
2seventy bio
TSVT
+$12.3M
5
BCAX
Bicara Therapeutics
BCAX
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CDTX
51
DELISTED
Cidara Therapeutics
CDTX
$11.1M 0.11%
+227,272
New +$5.46M
ACLX
52
DELISTED
Arcellx
ACLX
$11M 0.11%
+166,825
New +$10.4M
NUVL
53
DELISTED
Nuvalent
NUVL
$11M 0.11%
+143,937
New +$10.5M
SYRE icon
54
Spyre Therapeutics
SYRE
$8.48B
$9.38M 0.09%
+626,703
New +$9.27M
TSHA icon
55
Taysha Gene Therapies
TSHA
$1.61B
$9.25M 0.09%
4,004,756
– –
PRLD icon
56
Prelude Therapeutics
PRLD
$376M
$8.19M 0.08%
10,123,824
– –
CRNX icon
57
Crinetics Pharmaceuticals
CRNX
$8.88B
$8.05M 0.08%
+280,000
New +$8.65M
CTMX icon
58
CytomX Therapeutics
CTMX
$690M
$7.91M 0.08%
+3,484,226
New +$5.62M
SGMT icon
59
Sagimet Biosciences
SGMT
$433M
$7.26M 0.07%
952,996
– –
SION
60
Sionna Therapeutics
SION
$2.03B
$6.94M 0.07%
400,000
– –
AGIO icon
61
Agios Pharmaceuticals
AGIO
$2.08B
$6.31M 0.06%
+189,866
New +$5.75M
RAPP
62
Rapport Therapeutics
RAPP
$1.95B
$6.25M 0.06%
+550,090
New +$5.84M
SKYE icon
63
Skye Bioscience
SKYE
$21.4M
$6.06M 0.06%
1,450,638
– –
DSGN icon
64
Design Therapeutics
DSGN
$750M
$5.77M 0.06%
1,712,882
-30,843
-2% -$115K
KALA icon
65
KALA BIO
KALA
$12.9M
$5.72M 0.06%
24,038
– –
SANA icon
66
Sana Biotechnology
SANA
$882M
$5.54M 0.05%
2,030,949
– –
XNCR icon
67
Xencor
XNCR
$1.45B
$5.27M 0.05%
670,431
– –
ALMS
68
Alumis Inc
ALMS
$3.36B
$4.69M 0.05%
1,562,500
– –
IGMS
69
DELISTED
IGM Biosciences
IGMS
$4.59M 0.04%
4,096,210
+953
+0% +$1.16K
TCRX icon
70
TScan Therapeutics
TCRX
$48.5M
$4.04M 0.04%
2,784,792
– –
RLAY icon
71
Relay Therapeutics
RLAY
$4B
$4.01M 0.04%
1,160,117
– –
FATE icon
72
Fate Therapeutics
FATE
$276M
$2.78M 0.03%
2,485,018
-773,384
-24% -$899K
VIR icon
73
Vir Biotechnology
VIR
$1.46B
$2.73M 0.03%
542,539
– –
ELVN icon
74
Enliven Therapeutics
ELVN
$3.78B
$2.3M 0.02%
114,833
– –
WVE icon
75
Wave Life Sciences
WVE
$1.12B
$2.24M 0.02%
344,063
– –
1 2
3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Baker Bros. Advisors held 100 positions worth $10.3B, up 14% from $9.04B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors deployed $755M of net new capital in Q2 2025, opening 12 new positions and adding to 23 existing holdings. Its largest new stake was Viridian Therapeutics: 1,744,406 shares worth $24.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was argenx, an estimated $23.2M trimmed.

  • Baker Bros. Advisors's largest Q2 2025 buy was Viridian Therapeutics: 1,744,406 shares worth $24.4M.
  • Baker Bros. Advisors added most to Summit Therapeutics in Q2 2025, an estimated $212M increase.
  • Baker Bros. Advisors's biggest Q2 2025 reduction was argenx, cutting an estimated $23.2M.
  • Baker Bros. Advisors fully exited CRISPR Therapeutics in Q2 2025, selling an estimated $22.3M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $10.3B portfolio in Q2 2025.
  • Baker Bros. Advisors opened 12 new positions and closed 11 in Q2 2025.
  • Baker Bros. Advisors's portfolio value rose 14% quarter-over-quarter to $10.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.